Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models

Lorena Lobos-Gonzalez, Lorena Aguilar-Guzmán, Jaime G. Fernandez, Nicolas Muñoz, Mehnaz Hossain, Simone Bieneck, Veronica Silva, Veronica Burzio, Elena V. Sviderskaya, Dorothy C. Bennett, Lisette Leyton, Andrew F G Quest

Resultado de la investigación: Contribución a la publicaciónArticle

  • 5 Citas

Resumen

Melanomas are highly lethal skin tumours that are frequently treated by surgical resection. However, the efficacy of such procedures is often limited by tumour recurrence and metastasis. Caveolin-1 (CAV1) has been attributed roles as a tumour suppressor, although in late-stage tumours, its presence is associated with enhanced metastasis. The expression of this protein in human melanoma development and particularly how the presence of CAV1 affects metastasis after surgery has not been defined. CAV1 expression in human melanocytes and melanomas increases with disease progression and is highest in metastatic melanomas. The effect of increased CAV1 expression can then be evaluated using B16F10 murine melanoma cells injected into syngenic immunocompetent C57BL/6 mice or human A375 melanoma cells injected into immunodeficient B6Rag1-/- mice. Augmented CAV1 expression suppresses tumour formation upon a subcutaneous injection, but enhances lung metastasis of cells injected into the tail vein in both models. A procedure was initially developed using B16F10 melanoma cells in C57BL/6 mice to mimic better the situation in patients undergoing surgery. Subcutaneous tumours of a defined size were removed surgically and local tumour recurrence and lung metastasis were evaluated after another 14 days. In this postsurgery setting, CAV1 presence in B16F10 melanomas favoured metastasis to the lung, although tumour suppression at the initial site was still evident. Similar results were obtained when evaluating A375 cells in B6Rag1-/- mice. These results implicate CAV1 expression in melanomas as a marker of poor prognosis for patients undergoing surgery as CAV1 expression promotes experimental lung metastasis in two different preclinical models.

Idioma originalEnglish
Páginas (desde - hasta)108-119
Número de páginas12
PublicaciónMelanoma Research
Volumen24
Número de edición2
Identificadores de objetos digitales
EstadoPublished - 2014

Huella dactilar

Caveolin 1
Melanoma
Neoplasm Metastasis
Neoplasms
Lung
Inbred C57BL Mouse
Recurrence
Melanocytes
Human Development
Subcutaneous Injections
Disease Progression
Veins
Skin
Proteins

Keywords

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology
    • Dermatology
    • Medicine(all)

    Citar esto

    Lobos-Gonzalez, L., Aguilar-Guzmán, L., Fernandez, J. G., Muñoz, N., Hossain, M., Bieneck, S., ... Quest, A. F. G. (2014). Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. Melanoma Research, 24(2), 108-119. DOI: 10.1097/CMR.0000000000000046

    Lobos-Gonzalez, Lorena; Aguilar-Guzmán, Lorena; Fernandez, Jaime G.; Muñoz, Nicolas; Hossain, Mehnaz; Bieneck, Simone; Silva, Veronica; Burzio, Veronica; Sviderskaya, Elena V.; Bennett, Dorothy C.; Leyton, Lisette; Quest, Andrew F G / Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models.

    En: Melanoma Research, Vol. 24, N.º 2, 2014, p. 108-119.

    Resultado de la investigación: Contribución a la publicaciónArticle

    @article{a0afd3afc5104f8da8737a1042a74cf9,
    title = "Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models",
    abstract = "Melanomas are highly lethal skin tumours that are frequently treated by surgical resection. However, the efficacy of such procedures is often limited by tumour recurrence and metastasis. Caveolin-1 (CAV1) has been attributed roles as a tumour suppressor, although in late-stage tumours, its presence is associated with enhanced metastasis. The expression of this protein in human melanoma development and particularly how the presence of CAV1 affects metastasis after surgery has not been defined. CAV1 expression in human melanocytes and melanomas increases with disease progression and is highest in metastatic melanomas. The effect of increased CAV1 expression can then be evaluated using B16F10 murine melanoma cells injected into syngenic immunocompetent C57BL/6 mice or human A375 melanoma cells injected into immunodeficient B6Rag1-/- mice. Augmented CAV1 expression suppresses tumour formation upon a subcutaneous injection, but enhances lung metastasis of cells injected into the tail vein in both models. A procedure was initially developed using B16F10 melanoma cells in C57BL/6 mice to mimic better the situation in patients undergoing surgery. Subcutaneous tumours of a defined size were removed surgically and local tumour recurrence and lung metastasis were evaluated after another 14 days. In this postsurgery setting, CAV1 presence in B16F10 melanomas favoured metastasis to the lung, although tumour suppression at the initial site was still evident. Similar results were obtained when evaluating A375 cells in B6Rag1-/- mice. These results implicate CAV1 expression in melanomas as a marker of poor prognosis for patients undergoing surgery as CAV1 expression promotes experimental lung metastasis in two different preclinical models.",
    keywords = "Caveolin-1, Immunodeficient B6Rag1 -/-, Promoter of metastasis, Surgical resection, Syngenic immunocompetent C57BL/6",
    author = "Lorena Lobos-Gonzalez and Lorena Aguilar-Guzmán and Fernandez, {Jaime G.} and Nicolas Muñoz and Mehnaz Hossain and Simone Bieneck and Veronica Silva and Veronica Burzio and Sviderskaya, {Elena V.} and Bennett, {Dorothy C.} and Lisette Leyton and Quest, {Andrew F G}",
    year = "2014",
    doi = "10.1097/CMR.0000000000000046",
    volume = "24",
    pages = "108--119",
    journal = "Melanoma Research",
    issn = "0960-8931",
    publisher = "Lippincott Williams and Wilkins",
    number = "2",

    }

    Lobos-Gonzalez, L, Aguilar-Guzmán, L, Fernandez, JG, Muñoz, N, Hossain, M, Bieneck, S, Silva, V, Burzio, V, Sviderskaya, EV, Bennett, DC, Leyton, L & Quest, AFG 2014, 'Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models' Melanoma Research, vol. 24, n.º 2, pp. 108-119. DOI: 10.1097/CMR.0000000000000046

    Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. / Lobos-Gonzalez, Lorena; Aguilar-Guzmán, Lorena; Fernandez, Jaime G.; Muñoz, Nicolas; Hossain, Mehnaz; Bieneck, Simone; Silva, Veronica; Burzio, Veronica; Sviderskaya, Elena V.; Bennett, Dorothy C.; Leyton, Lisette; Quest, Andrew F G.

    En: Melanoma Research, Vol. 24, N.º 2, 2014, p. 108-119.

    Resultado de la investigación: Contribución a la publicaciónArticle

    TY - JOUR

    T1 - Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models

    AU - Lobos-Gonzalez,Lorena

    AU - Aguilar-Guzmán,Lorena

    AU - Fernandez,Jaime G.

    AU - Muñoz,Nicolas

    AU - Hossain,Mehnaz

    AU - Bieneck,Simone

    AU - Silva,Veronica

    AU - Burzio,Veronica

    AU - Sviderskaya,Elena V.

    AU - Bennett,Dorothy C.

    AU - Leyton,Lisette

    AU - Quest,Andrew F G

    PY - 2014

    Y1 - 2014

    N2 - Melanomas are highly lethal skin tumours that are frequently treated by surgical resection. However, the efficacy of such procedures is often limited by tumour recurrence and metastasis. Caveolin-1 (CAV1) has been attributed roles as a tumour suppressor, although in late-stage tumours, its presence is associated with enhanced metastasis. The expression of this protein in human melanoma development and particularly how the presence of CAV1 affects metastasis after surgery has not been defined. CAV1 expression in human melanocytes and melanomas increases with disease progression and is highest in metastatic melanomas. The effect of increased CAV1 expression can then be evaluated using B16F10 murine melanoma cells injected into syngenic immunocompetent C57BL/6 mice or human A375 melanoma cells injected into immunodeficient B6Rag1-/- mice. Augmented CAV1 expression suppresses tumour formation upon a subcutaneous injection, but enhances lung metastasis of cells injected into the tail vein in both models. A procedure was initially developed using B16F10 melanoma cells in C57BL/6 mice to mimic better the situation in patients undergoing surgery. Subcutaneous tumours of a defined size were removed surgically and local tumour recurrence and lung metastasis were evaluated after another 14 days. In this postsurgery setting, CAV1 presence in B16F10 melanomas favoured metastasis to the lung, although tumour suppression at the initial site was still evident. Similar results were obtained when evaluating A375 cells in B6Rag1-/- mice. These results implicate CAV1 expression in melanomas as a marker of poor prognosis for patients undergoing surgery as CAV1 expression promotes experimental lung metastasis in two different preclinical models.

    AB - Melanomas are highly lethal skin tumours that are frequently treated by surgical resection. However, the efficacy of such procedures is often limited by tumour recurrence and metastasis. Caveolin-1 (CAV1) has been attributed roles as a tumour suppressor, although in late-stage tumours, its presence is associated with enhanced metastasis. The expression of this protein in human melanoma development and particularly how the presence of CAV1 affects metastasis after surgery has not been defined. CAV1 expression in human melanocytes and melanomas increases with disease progression and is highest in metastatic melanomas. The effect of increased CAV1 expression can then be evaluated using B16F10 murine melanoma cells injected into syngenic immunocompetent C57BL/6 mice or human A375 melanoma cells injected into immunodeficient B6Rag1-/- mice. Augmented CAV1 expression suppresses tumour formation upon a subcutaneous injection, but enhances lung metastasis of cells injected into the tail vein in both models. A procedure was initially developed using B16F10 melanoma cells in C57BL/6 mice to mimic better the situation in patients undergoing surgery. Subcutaneous tumours of a defined size were removed surgically and local tumour recurrence and lung metastasis were evaluated after another 14 days. In this postsurgery setting, CAV1 presence in B16F10 melanomas favoured metastasis to the lung, although tumour suppression at the initial site was still evident. Similar results were obtained when evaluating A375 cells in B6Rag1-/- mice. These results implicate CAV1 expression in melanomas as a marker of poor prognosis for patients undergoing surgery as CAV1 expression promotes experimental lung metastasis in two different preclinical models.

    KW - Caveolin-1

    KW - Immunodeficient B6Rag1 -/-

    KW - Promoter of metastasis

    KW - Surgical resection

    KW - Syngenic immunocompetent C57BL/6

    UR - http://www.scopus.com/inward/record.url?scp=84896404941&partnerID=8YFLogxK

    U2 - 10.1097/CMR.0000000000000046

    DO - 10.1097/CMR.0000000000000046

    M3 - Article

    VL - 24

    SP - 108

    EP - 119

    JO - Melanoma Research

    T2 - Melanoma Research

    JF - Melanoma Research

    SN - 0960-8931

    IS - 2

    ER -

    Lobos-Gonzalez L, Aguilar-Guzmán L, Fernandez JG, Muñoz N, Hossain M, Bieneck S y otros. Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. Melanoma Research. 2014;24(2):108-119. Disponible desde, DOI: 10.1097/CMR.0000000000000046